Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | Pomoč | SLO | ENG

Naslov:CCR5 Δ32 and CTLA-4 +49 A/G gene polymorphisms and interferon-β treatment response in Croatian and Slovenian multiple sclerosis patients
Avtorji:ID Nekić, Jasna (Avtor)
ID Stanković Matić, Ivana (Avtor)
ID Rački, Valentino (Avtor)
ID Janko Labinac, Dolores (Avtor)
ID Vuletić, Vladimira (Avtor)
ID Kapović, Miljenko (Avtor)
ID Ristić, Smiljana (Avtor)
ID Peterlin, Borut (Avtor)
ID Starčević-Čizmarević, Nada (Avtor)
Datoteke:.pdf PDF - Predstavitvena datoteka, prenos (271,56 KB)
MD5: 6EEF687C14AC351D146B8D5DCBEC461A
 
URL URL - Izvorni URL, za dostop obiščite https://doi.org/10.3390/ijms25137412
 
Jezik:Angleški jezik
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:Logo UKC LJ - Univerzitetni klinični center Ljubljana
Povzetek:The aim of the present study was to investigate the impact of CCR5 Δ32 and CTLA-4 polymorphisms on the response to IFN-β treatment in our cohort of MS patients from Croatia and Slovenia. Genomic DNA was obtained from 295 MS patients (230 female; 65 male) classified as responders (n = 173) and non-responders (n = 122) based on clinical criteria for treatment efficacy. Genotyping was performed via PCR/PCR-RFLP. No significant differences in the genotype/allele frequencies of CCR5Δ32 and CTLA-4 +49 A/G were detected between male responders and nonresponders. A significantly higher prevalence (p = 0.039) of the CTLA-4 +49 AA genotype was found in female responders (42.1%) compared to non-responders (28.9%). Using multiple forward regression analysis, the CTLA-4 +49 AA genotype significantly predicted a positive response to IFN-β therapy in females (p = 0.011) and contributed to 4.5% of response variability. Furthermore, the combined presence of the CCR5Δ32 wtwt/CTLA-4 +49 AA genotype significantly predicted a positive response to treatment in females (p = 0.025). The age at disease onset, pretreatment relapse rate, and baseline EDSS score were not reliable predictors of treatment response in MS patients. Our results indicate that the presence of the CCR5Δ32 polymorphism was not associated with the response to IFN-β treatment, whereas the CTLA-4 +49 polymorphism showed a positive correlation with an optimal response in female patients.
Ključne besede:multiple sclerosis, polymorphism, treatment response, interferon-β
Status publikacije:Objavljeno
Verzija publikacije:Objavljena publikacija
Leto izida:2024
Št. strani:str. 1-11
Številčenje:Vol. 25, iss. 13, [article no.] 7412
PID:20.500.12556/DiRROS-28094 Novo okno
UDK:616.8
ISSN pri članku:1422-0067
DOI:10.3390/ijms25137412 Novo okno
COBISS.SI-ID:239992835 Novo okno
Opomba:Nasl. z nasl. zaslona; Opis vira z dne 19. 6. 2025;
Datum objave v DiRROS:10.03.2026
Število ogledov:36
Število prenosov:19
Metapodatki:XML DC-XML DC-RDF
:
Kopiraj citat
  
Objavi na:Bookmark and Share


Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.

Gradivo je del revije

Naslov:International journal of molecular sciences
Skrajšan naslov:Int. j. mol. sci.
Založnik:MDPI
ISSN:1422-0067
COBISS.SI-ID:2779162 Novo okno

Gradivo je financirano iz projekta

Financer:Drugi - Drug financer ali več financerjev
Program financ.:University of Rijeka
Številka projekta:uniri-biomed-18-137
Naslov:Farmakogenetika multiple skleroze: odgovor na imunomodulacijsku terapiju

Licence

Licenca:CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.

Nazaj